1. Long-term survival in a patient with supratentorial glioblastoma: clinical considerations
- Author
-
Paolo Celli, Maurizio Salvati, and Luigi Cervoni
- Subjects
medicine.medical_specialty ,Nitrosourea ,Neurology ,Adolescent ,medicine.medical_treatment ,Dermatology ,Giant Cells ,Disease-Free Survival ,Necrosis ,chemistry.chemical_compound ,medicine ,Humans ,External beam radiotherapy ,Neuroradiology ,Diplopia ,Chemotherapy ,Brain Neoplasms ,business.industry ,General Neuroscience ,General Medicine ,Prognosis ,Combined Modality Therapy ,Surgery ,Psychiatry and Mental health ,Treatment Outcome ,chemistry ,Radiological weapon ,Female ,Neurology (clinical) ,Neurosurgery ,medicine.symptom ,Glioblastoma ,business - Abstract
Glioblastoma, a malignant tumor of neuroepithelial origin, is relatively uncommon in childhood, during which it accounts for 7%-9% of brain tumors. A few patients (about 3%) live more than 5 years. We report a 13-year-old girl who was admitted because one month earlier she had begun to present headache and diplopia. Brain computed tomography (CT) showed a right frontal tumor. At operation, complete excision of the visible tumor was performed. Histologic examination showed that the tumor was a glioblastoma multiforme. The patient underwent 52 Gy of external beam radiotherapy to the enhancing tumor mass plus 3-cm border, and chemotherapy with nitrosourea (BCNU). Fourteen years, 9 months later, the patient presents neither neurological deficits nor radiological relapse. We confirm that younger age, the one immutable prognostic factor, supports a particularly aggressive approach to the treatment of glioblastomas.
- Published
- 1998
- Full Text
- View/download PDF